FDA Approves Ixekizumab (Taltz) for Nonradiographic axSpA FDA Approves Ixekizumab (Taltz) for Nonradiographic axSpA
The monoclonal interleukin-17A antagonist has three other indications: ankylosing spondylitis in adults, psoriatic arthritis in adults, and plaque psoriasis in adults and children age 6 and older.Medscape Medical News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Rheumatology News Source Type: news
More News: Ankylosing Spondylitis | Arthritis | Children | Dermatology | Psoriasis | Psoriatic Arthritis | Rheumatology | Skin